This is a working overview of counterion, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-12-22. Anything still debated is marked as such rather than presented as settled.
Peptides are susceptible to hydrolysis, oxidation, and aggregation, and BPC-157 is no exception. The lyophilized powder form is generally more stable than a solution because residual moisture is low and molecular mobility is reduced. Once dissolved, the peptide is exposed to water, oxygen, and trace metal ions that accelerate degradation. Light exposure and repeated freeze-thaw cycles are also commonly cited as sources of loss. These general principles guide most handling recommendations found in supplier documentation.
Standard practice for the solid form is storage at minus twenty degrees Celsius or colder, kept dry and away from light. Containers are usually sealed with a desiccant to limit moisture uptake. Reconstituted solutions are typically held at two to eight degrees Celsius and used within a short window, because potency can decline over days to weeks depending on the buffer and concentration. Freezing an already dissolved sample may help, though repeated thawing is discouraged. Specific shelf-life claims vary between suppliers and are rarely supported by published stability studies.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometers, a wavelength that captures the peptide backbone. The main peak area is reported as a percentage of total peak area, which serves as a conventional purity figure. Mass spectrometry provides an independent check on molecular mass and helps confirm the expected sequence. Additional tests may include amino acid analysis and water content determination. Results are only comparable when the same column, gradient, and detection settings are used.
Proposed mechanisms in the literature involve the nitric oxide system, vascular endothelial growth factor signaling, and epidermal growth factor receptor pathways. Some studies report changes in blood vessel formation or in inflammatory mediators, while others describe interactions with nervous tissue. Much of this evidence rests on molecular markers in cultured cells or animal models. Whether the same pathways operate the same way in humans has not been established. Authors therefore tend to describe mechanisms as hypothetical rather than settled.
Direct human evidence is scarce. One trial in ulcerative colitis delivered the compound by enema and produced limited publicly reported results without a clear benefit. The compound is not an approved medicine in most jurisdictions. In many markets it is sold as a research chemical; in others it falls under prescription or controlled categories. Regulators have not confirmed any claimed medical use, and product labels rarely undergo premarket review.
| Property | Value | Notes |
|---|---|---|
| Lyophilized powder storage | -20 C or colder, desiccated, protected from light | Long-term condition cited in supplier documentation |
| Reconstituted solution storage | 2-8 C for short-term use | Stability decreases after dissolution |
| Appearance | White to off-white lyophilized powder | Used as a visual identity check |
| Solubility | Soluble in water and aqueous buffers | Limited solubility in nonpolar organic solvents |
| Typical analytical method | Reversed-phase HPLC with UV detection at 214 nm | Purity estimate; mass spectrometry confirms molecular mass |
Terminology in the literature is not fully standardised. Papers and product listings use BPC-157, BPC 157, and the longer phrase stable gastric pentadecapeptide BPC 157 interchangeably, and synonyms such as bepecin or PL 14736 appear in older or company-linked publications. Purity claims and reported masses can also differ between sources because peptide preparations may include counterions, residual solvents, or bound water. This variability complicates direct comparison of results across studies and makes the exact identity and grade of a given sample worth verifying. Discussions of the compound should therefore specify the source, salt form, and stated purity where those are known.
BPC-157 is a synthetic peptide composed of fifteen amino acid residues, with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Its name derives from body protection compound, a term used for a protein fraction identified in human gastric juice. Researchers in Zagreb first reported the pentadecapeptide in the early 1990s and described it as a stable fragment of that larger protein. The compound is also catalogued as PL 14736 and, in some commercial contexts, as bepecin. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Most published work on BPC-157 consists of preclinical studies, including rodent models of tissue injury, gastrointestinal lesions, and vascular or tendon damage, together with in vitro cell assays. Reviews frequently note that the mechanisms proposed in these papers remain incompletely characterised and that findings have not been confirmed in large randomised human trials. The compound is widely sold as a research chemical rather than a licensed medicine, and labels commonly carry a statement that it is not for human use. Whether any of the reported animal effects translate to humans is an open question rather than an established result.
Laboratory research on this peptide has examined a wide and heterogeneous set of endpoints, including gastric ulcer models, tendon and ligament injury, wound closure, and intestinal inflammation. Most published findings come from rodent studies, and reported effect sizes are often large relative to controls. Because the compound has been tested across many unrelated injury models, the literature is frequently described as unusually broad for a single peptide. A substantial share of this work originates from a small number of research groups, which matters when assessing how widely results have been reproduced.
Evidence in humans is limited. Small clinical studies have examined the peptide in contexts such as ulcerative colitis and wound healing, but participant numbers are small and independent replication is scarce. It is not approved as a medicine by major regulatory agencies and is distributed mainly as a research material or compounded preparation. Long-term human safety data are not established, and questions about absorption through non-injected routes remain open rather than resolved. Claims about its effects are best read against these gaps.
BPC-157 is normally distributed as a lyophilised powder that ranges from white to off-white in appearance. The peptide dissolves readily in water, normal saline, and common aqueous buffers, and it is poorly soluble in nonpolar solvents such as hexane or vegetable oils. Lyophilised vials take up moisture if left open, which changes the mass of powder in the container and complicates any later weighing. Because the material is handled in small quantities, static and adhesion to glass or plastic can also cause noticeable losses during transfer.
The main chemical liabilities of this sequence are peptide-bond hydrolysis and possible aspartate-related reactions, since the peptide contains aspartic acid residues but no cysteine, methionine, or tryptophan. Absence of those three residues removes the most common oxidation and disulfide pathways from consideration. Studies of related peptides indicate that aspartate isomerisation and aspartimide formation occur most readily at Asp-Gly and Asp-Ala positions, and open questions remain about how quickly those reactions proceed under ordinary laboratory conditions. Storage guidance typically emphasises cool, dry, dark conditions to slow hydrolysis.
In striated skeletal muscle cells, GLUT4 concentration in the plasma membrane can increase as a result of either exercise or muscle contraction. During exercise, the body needs to convert glucose to ATP to be used as energy. As G-6-P concentrations decrease, hexokinase becomes less inhibited, and the glycolytic and oxidative pathways that make ATP are able to proceed. This also means that muscle cells are able to take in more glucose as its intracellular concentrations decrease. In order to increase glucose levels in the cell, GLUT4 is the primary transporter used in this facilitated diffusion. Although muscle contractions function in a similar way and also induce the translocation of GLUT4 into the plasma membrane, the two skeletal muscle processes obtain different forms of intracellular GLUT4. The GLUT4 carrier vesicles are either transferrin positive or negative, and are recruited by different stimuli. Transferrin-positive GLUT4 vesicles are utilized during muscle contraction while the transferrin-negative vesicles are activated by insulin stimulation as well as by exercise.
=== Hypoaldosteronism === An ACTH stimulation test for aldosterone can help in determining the cause of hypoaldosteronism, with a low aldosterone response indicating a primary hypoaldosteronism of the adrenals, while a large response indicating a secondary hypoaldosteronism. The most common cause of this condition (and related symptoms) is Addison's disease; it is typically treated by fludrocortisone, which has a much longer persistence (1 day) in the bloodstream.
The data are obtained within 1–2 h and include unique quality control measures through the GFP signal. DSF-GTP has been applied for the characterization of proteins and the screening of small compounds.
Several scientists, such as William Prout and Norman Lockyer, had suggested that atoms were built up from a more fundamental unit, but they envisioned this unit to be the size of the smallest atom, hydrogen. Thomson in 1897 was the first to suggest that one of the fundamental units of the atom was more than 1,000 times smaller than an atom, suggesting the subatomic particle now known as the electron. Thomson discovered this through his explorations on the properties of cathode rays. Thomson made his suggestion on 30 April 1897 following his discovery that cathode rays (at the time known as Lenard rays) could travel much further through air than expected for an atom-sized particle. He estimated the mass of cathode rays by measuring the heat generated when the rays hit a thermal junction and comparing this with the magnetic deflection of the rays. His experiments suggested not only that cathode rays were over 1,000 times lighter than the hydrogen atom, but also that their mass was the same in whichever type of atom they came from. He concluded that the rays were composed of very light, negatively charged particles which were a universal building block of atoms. He called the particles "corpuscles", but later scientists preferred the name electron, which had been suggested by George Johnstone Stoney in 1891, prior to Thomson's discovery. In April 1897, Thomson had only early indications that the cathode rays could be deflected electrically (previous investigators such as Heinrich Hertz had thought they could not be).
Sources: en.wikipedia.org
== Timeline overview == The table below displays all national recessions appearing in 2006–2013 (for the 71 countries with available data), according to the common recession definition, saying that a recession occurred whenever seasonally adjusted real GDP contracts quarter on quarter, through minimum two consecutive quarters. Only 11 out of the 71 listed countries with quarterly GDP data (Poland, Slovakia, Moldova, India, China, South Korea, Indonesia, Australia, Uruguay, Colombia and Bolivia) escaped a recession in this time period. The few recessions appearing early in 2006–07 are commonly never associated to be part of the Great Recession, which is illustrated by the fact that only two countries (Iceland and Jamaica) were in recession in Q4 2007. One year before the maximum, in Q1 2008, only six countries were in recession (Iceland, Sweden, Finland, Ireland, Portugal and New Zealand). The number of countries in recession was 25 in Q2 2008, 39 in Q3 2008 and 53 in Q4 2008. At the steepest part of the Great Recession in Q1 2009, a total of 59 out of 71 countries were simultaneously in recession. The number of countries in recession was 37 in Q2 2009, 13 in Q3 2009 and 11 in Q4 2009. One year after the maximum, in Q1 2010, only seven countries were in recession (Greece, Croatia, Romania, Iceland, Jamaica, Venezuela and Belize). The recession data for the overall G20 zone (representing 85% of all GWP), depict that the Great Recession existed as a global recession throughout Q3 2008 until Q1 2009.
== Causes == MS is an autoimmune disease with a combination of genetic and environmental causes underlying it. Both T cells and B cells are involved. The causes of the disease are not fully understood. The Epstein-Barr Virus (EBV) very strongly increases the risk of MS.
== See also == Anthropogenic metabolism – Material and energy turnover of human society Antimetabolite – Chemical that inhibits the use of a metabolite Battery theory Calorimetry – Determining heat transfer in a system by measuring its other properties Isothermal microcalorimetry – Measuring versus elapsed time the net rate of heat flow Inborn errors of metabolism – Class of genetic diseases Iron–sulfur world hypothesis – Hypothetical scenario for the origin of life, a "metabolism first" theory of the origin of life Metabolic disorder – Any disease hindering the body's ability to process and distribute nutrients Microphysiometry Primary nutritional groups – Group of organisms Proto-metabolism – Chemical reactions which turn into modern metabolism Respirometry – Estimation of metabolic rates by measuring heat production Stream metabolism Sulfur metabolism – Set of chemical reactions involving sulfur in living organisms Thermic effect of food – Energy expenditure for processing food Urban metabolism – Model of the flows of materials and energy in cities Water metabolism – Aspect of homeostasis concerning control of the amount of water in an organism Overflow metabolism – Cellular phenomena Oncometabolism Reactome – Database of biological pathways KEGG – Collection of bioinformatics databases
=== Phagocytosis === Half-maximum stimulation is attained at about 100 nM. Stimulation of phagocytosis is obtained with polymorphonuclear leukocyte (PMN) cells from human, dog, rabbit and cow as well as with macrophages from the lung and peritoneal cavity of mice, guinea pig and mouse bone marrow cells. This effect is inhibited by peptide analogue Thr-Lys-Pro-Pro-Arg. Basal activity is not inhibited, so basal phagocytosis may follow a different pathway from that which follows stimulation. Stimulation of pinocytosis is exerted only on phagocytic cells, not on cultured cell line mouse leukemia.
==== Lipid complex formulations ==== Several lipid complex preparations are also available. Abelcet was approved by the FDA in 1995. It consists of amphotericin B and two lipids in a 1:1 ratio that form large ribbon-like structures. Amphotec is a complex of amphotericin and sodium cholesteryl sulfate in a 1:1 ratio. Two molecules of each form a tetramer that aggregates into spiral arms on a disk-like complex. It was approved by the FDA in 1996.
Sources: en.wikipedia.org
When glucose has been converted into G6P by hexokinase or glucokinase, it can either be converted to glucose-1-phosphate (G1P) for conversion to glycogen, or it is alternatively converted by glycolysis to pyruvate, which enters the mitochondrion where it is converted into acetyl-CoA and then into citrate. Excess citrate is exported from the mitochondrion back into the cytosol, where ATP citrate lyase regenerates acetyl-CoA and oxaloacetate (OAA). The acetyl-CoA is then used for fatty acid synthesis and cholesterol synthesis, two important ways of utilizing excess glucose when its concentration is high in blood. The regulated enzymes catalyzing these reactions perform these functions when they have been dephosphorylated through the action of insulin on the liver cells. Between meals, during fasting, exercise or hypoglycemia, glucagon and epinephrine are released into the blood. This causes liver glycogen to be converted back to G6P, and then converted to glucose by the liver-specific enzyme glucose 6-phosphatase and released into the blood. Glucagon and epinephrine also stimulate gluconeogenesis, which converts non-carbohydrate substrates into G6P, which joins the G6P derived from glycogen, or substitutes for it when the liver glycogen store have been depleted. This is critical for brain function, since the brain utilizes glucose as an energy source under most conditions. The simultaneously phosphorylation of, particularly, phosphofructokinase, but also, to a certain extent pyruvate kinase, prevents glycolysis occurring at the same time as gluconeogenesis and glycogenolysis.
The Rockefeller Foundation continued funding German eugenics research even after it was clear that it was being used to rationalize discrimination against Jewish people and other groups, after the Nuremberg laws in 1935. In 1936, Rockefeller fulfilled pledges of $655,000 to Kaiser Wilhelm Institute, even though several distinguished Jewish scientists had been dropped from the institute at the time. The Rockefeller Foundation did not alert the world about the racist implications of Nazi ideology, but furthered and funded eugenic research through the 1930s. Even into the 1950s, Rockefeller continued to provide some funding for research borne out of German eugenics. The foundation also funded the relocation of scholars threatened by the Nazis to America in the 1930s, known as the Refugee Scholar Program and the Emergency Committee in Aid of Displaced Foreign Scholars. Some of the notable figures relocated or saved, among a total of 303 scholars, were Thomas Mann, Claude Lévi-Strauss and Leó Szilárd. The foundation helped The New School provide a haven for scholars threatened by the Nazis.
Immunization, vaccine preventable diseases and polio transition World Health Organization WHO Vaccine Position Papers World Health Organization The History of Vaccines, from the College of Physicians of Philadelphia This website was highlighted by Genetic Engineering & Biotechnology News in its "Best of the Web" section in January 2015. See: "The History of Vaccines". Best of the Web. Genetic Engineering & Biotechnology News. Vol. 35, no. 2. 15 January 2015. p. 38.
== Awards and honours == Beynon received the Sigma Xi Research Award, Purdue University in 1973, the Marice F. Hasler Award in 1979, the Jozef Stefan Medal in 1980, the Medal of the Serbian Chemical Society in 1981, the Techmart Trophy of the British Technology Group in 1984, the Jan Marc Marci Medal, Czechoslovak Spectroscopic Society in 1984, the International Mass Spectrometry Society Thomson Medal in 1985, the American Chemical Society Field and Franklin Award for Outstanding Work in Mass Spectrometry in 1987, the British Mass Spectrometry Society Aston Medal in 1998, and the Italian Mass Spectrometry Society Gold Medal in 1990. He was the Founder chairman British Mass Spectrometry Society (1960), a founding member of the American Society for Mass Spectrometry (1967), and Founder President of the European Mass Spectrometry Society (1993). Beynon was elected to the Royal Society in 1971. He authored over 350 scientific publications. and several books on mass spectrometry. In 1987, Beynon was founding editor-in-chief of the journal Rapid Communications in Mass Spectrometry.
Sources: en.wikipedia.org
Reversed-phase HPLC separates the sample into peaks, and the main peak is expressed as a percentage of total peak area. Mass spectrometry is then used to confirm that the molecular mass matches the expected value.
Low temperature and low moisture slow hydrolysis and oxidation, the two main degradation routes for short peptides. A desiccant limits water uptake each time the vial is opened.
No single number captures identity, counter-ion content, water content, or sterility. A purity figure from one laboratory method reflects only what that method detects, and different methods can give different values for the same sample.
Animal experiments form the bulk of the published record. Rodent models of tendon, ligament, bone, and gut injury are the most common designs. Controlled human trials are rare, which limits confidence in any clinical claim.